2022-04-28-上交所-普莱柯2022年第一季度报告_11页_374kb

Financial Performance Summary for Phopolis Bioengineering (Q1 2022):

• Revenue: Total revenue was 245.3 million yuan, a 20.54% decrease from Q1 2021.
• Profit: Net profit attributable to shareholders was 37.5 million yuan, falling 56.80% year-over-year; adjusted net profit decreased 59.22%.
• Cash Flow: Operating cash flow was -8.5 million yuan, an improvement of 41.64% (less negative) due to lower spending on purchases and taxes.
• Other Metrics: Basic earnings per share were 0.12 yuan, down 57.14%; return on equity decreased.

Product Revenue Breakdown:

• Vaccines: Pig vaccines sales decreased 24.27% to 83.49 million yuan; poultry vaccines and antibodies fell 10.85% to 81.55 million yuan; chemical drugs dropped 29.20% to 71.01 million yuan.
• Technology: Licensing and transfers increased 74.74% to 6.64 million yuan, offsetting some revenue loss.

Key Financial Changes:

• Reasons: Revenue decline mainly due to reduced vaccine and drug sales, exacerbated by higher operating costs and interest changes. However, cash increased from loans and investment activities.

Shareholder Information:

• Top Shareholders: Zhang Xueto holds 107.6 million shares (33.47%), followed by others with significant stakes, including those from Central Financial Holdings and individual investors.
• Ownership: No major changes among top shareholders; some have pledged shares.